" class="no-js "lang="en-US"> Nexus Pharmaceuticals Announces launch of Sterile Vials Product
Tuesday, April 23, 2024

Nexus Pharmaceuticals Announces Launch of Sterile Vial Product Line

Nexus Pharmaceuticals announced the launch of its new product line – Sterile Vials from Nexus Pharmaceuticals. The product trio includes 20mL clear vials, 10mL clear vials, and 2mL amber vials with plans to expand the portfolio with a wider range of sizes.

“This development aligns with Nexus’ commitment to innovation and represents a progressive step in broadening our healthcare scope and addressing supply chain constraints in the market,” said Omair Ahmed, Chief Operating Officer of Nexus Pharmaceuticals. “We have designed this product for use in various settings, including research laboratories, healthcare clinics, and veterinary offices. This direct-to-consumer offering is a new and exciting venture for us, and we look forward to a closer relationship with our customers.”

The sterilized vials from Nexus Pharmaceuticals are available for purchase in cartons consisting of twenty-five vials. The pyrogen-free glass vials are manufactured at an FDA-inspected facility under GMP conditions. They feature FluroTec® Barrier Film technology, providing an effective barrier against extractables and leachables and minimizing the risk of impurities, interactions, and medicine degradation. The finished vial stoppers are composed of a latex- and rubber-free chlorobutyl formulation.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more